Marcelle Machluf
Fondateur chez NanoGhost Ltd.
Profil
Marcelle Machluf is the founder of NanoGhost Ltd.
which was founded in 2019.
She is currently an Associate Professor at Technion-Israel Institute of Technology.
Dr. Machluf was an External Director at Erech Finance Cahalacha Ltd.
from 2010 to 2019.
Dr. Machluf has an undergraduate degree from The Hebrew University of Jerusalem and graduate and doctorate degrees from Ben-Gurion University of the Negev.
Postes actifs de Marcelle Machluf
| Sociétés | Poste | Début |
|---|---|---|
| Technion-Israel Institute of Technology | Corporate Officer/Principal | - |
NanoGhost Ltd.
 NanoGhost Ltd. Packaged SoftwareTechnology Services NanoGhost Ltd. is an Israeli biotech company that specializes in developing a drug delivery platform called Nano-Ghosts/NGs. The company is based in Netanya, Israel. The platform is highly selective and is derived from the cell membrane of mesenchymal stem cells (MSCs), which have a known affinity for cancer and sites of inflammation. The company was founded in 2019 by Marcelle Machluf. Yonatan Malca has been the CEO of the company since 2019. | Fondateur | 14/08/2019 |
Anciens postes connus de Marcelle Machluf
| Sociétés | Poste | Fin |
|---|---|---|
| ERECH FINANCE CAHALACHA LTD | Directeur/Membre du Conseil | 27/10/2019 |
Formation de Marcelle Machluf
| Ben-Gurion University of the Negev | Doctorate Degree |
| The Hebrew University of Jerusalem | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ERECH FINANCE CAHALACHA LTD | Health Technology |
| Entreprise privées | 1 |
|---|---|
NanoGhost Ltd.
NanoGhost Ltd. Packaged SoftwareTechnology Services NanoGhost Ltd. is an Israeli biotech company that specializes in developing a drug delivery platform called Nano-Ghosts/NGs. The company is based in Netanya, Israel. The platform is highly selective and is derived from the cell membrane of mesenchymal stem cells (MSCs), which have a known affinity for cancer and sites of inflammation. The company was founded in 2019 by Marcelle Machluf. Yonatan Malca has been the CEO of the company since 2019. | Technology Services |
